NurExone Biologic

Company Overview

Snapshot

Founded in January 2020, NurExone Biologic operates with 11–50 employees. The company has raised a total of $9.53M across 8 funding rounds and went public on TSXV in July 2022.

Business overview

NurExone Biologic is a Health Tech & Life Sciences company focused on revolutionizing recovery from nervous system injuries by regenerating and rewiring neurons. The company develops a biological extracellular vesicles-based drug platform designed to treat damage in the Central Nerve System (CNS). Its novel approach to spinal cord injury (SCI) treatment utilizes intranasal exosome administration, offering an alternative to existing therapies. NurExone's technology, extensively researched at the Technion and Tel Aviv University, involves exosomes loaded with PTEN siRNA to target complete spinal cord lesions, demonstrating significant functional recovery in preclinical studies.

Strategic signal

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing process. This development is crucial for strengthening the company's supply chain readiness, indicating a significant step towards commercialization and scaling its proprietary drug platform for central nervous system treatments.

Company Intelligence Q&A

When did NurExone Biologic go public?

NurExone Biologic went public on TSXV in July 2022.

What significant regulatory milestone did NurExone Biologic achieve in October 2023?

In October 2023, NurExone Biologic received FDA Orphan-Drug Designation, accelerating the development of its ExoPTEN therapy for Acute Spinal Cord Injury Treatment.

What was a key development for NurExone Biologic in September 2025?

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing, strengthening its supply chain readiness.

What was the outcome of NurExone Biologic's preclinical study in September 2024?

In September 2024, NurExone Biologic demonstrated an extended therapeutic window of ExoPTEN post Spinal-Cord Injury in a preclinical study.